Meda Pharma allergic rhinitis drug Dymista gets UK MHRA approval
Dymista is indicated for patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief. The new nasal spray
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.